• Turning Breakthrough
  • Discoveries  into Medicines

About Us

About Us

1STBIO is dedicated to developing breakthrough therapies with a key value to provide novel medicines to patients. We are focused on discovery and development of innovative first-in-class therapeutic candidates with highly likelihood of clinical success. 1STBIO currently has 24 employees with expertise in biochemistry, medicinal chemistry, pharmacology, and business development. We are working as a core expertise team of drug discovery/development and are rigorously connected to R&D networking of academia, hospitals, industry, CRO’s and investors in Korea, China and US. Our ultimate goal is to use our experience and knowledge to discover and develop effective molecular therapeutics for patients.



Therapeutic Focus

Neurodegenerative Diseases


Orphan diseases

R&D pipeline

1ST-102 targets c-Abl, which has been shown to play a critical role in driving alpha-synuclein pathogenesis in Parkinson’s disease. Our current candidate has optimal properties as CNS drug with potent neuroprotection activities and desirable safety profiles. We expect to file phase I IND in 2018 and we believe that it will be the first c-Abl inhibitor to advance into clinical trials, with optimal target engagement, CNS behaviors and safety profiles necessary for treatment of Parkinson’s disease with high potential as disease-modifying agent.

1ST-101 and 1ST-103 are in discovery stage as approaches to inhibit neuroinflammation associated with various neurodegenerative diseases. 1ST-101 and 1ST-103 block a critical pathway in vicious inflammatory response followed by neurotoxicity, which leads to disease-modifying potential and broad-spectrum therapeutic options for Parkinson’s, Alzheimer’s and ALS.

1ST-201 targets a crucial pathway in immuno-oncology and aims to reverse the active immune suppression and stimulate functionality of effector immune cells and dendritic cells in tumor microenvironment. We envision that 1ST-201 will provide novel therapeutic option as well as beneficial part of combination in immunotherapy with the objective of modulating multiple therapeutic opportunities for maximum benefits to cancer patients.



CEO and Founder
Jamie Jae Eun Kim, Ph.D.

Jamie Jae Eun Kim has founded 1ST Biotherapeutics, Inc. in 2016 and has been served as CEO since then, bringing a wealth of scientific leadership and business expertise. She has been engaged in all aspects of drug discovery and development as well as business development, with a particular focus on cancers, metabolic diseases and orphan diseases. Jamie has deep experience brokering R&D strategies and portfolio management in pharma R&D, with track record of over 50 successful R&D alliances among biotech, academia, clinical research units and industry throughout her career.

Previously, Jamie was Director of the Biotherapeutics Research Center at Handok, where she was responsible for several development programs in oncology and rare diseases and for research alliance and investment. She was an Associate Director at Green Cross Corp. (Now GC Pharma), where she has newly established a discovery team in oncology and rare diseases, and, prior to that, she was a Collaboration Project Leader at Sanofi, leading collaborative research effort in oncology. Jamie spent her early career doing metabolic and oncology research leading discovery projects as a Senior Scientist at Wyeth in Pearl River, NY. She is a current member of the Global Pharma Key Opinion Leader (GPKOL) consultants and a former member of the Korea Drug Development Fund (KDDF) investment committee.

Jamie has a bachelor’s in bioengineering and master’s degree in biological science from KAIST (Korea Advanced Institute of Science and Technology). she graduated with a Ph.D. in cell and structural biology from the University of Illinois at Urbana Champaign, USA.

Chief Technology Officer
Jinhwa Lee, Ph.D.

Jinhwa Lee has an accomplished career in drug discovery spanning academia and industry. He has helped identify and advance novel anti-bacterials, anti-virals, anti-coagulants, and therapies for metabolic syndrome, CNS disorders, and cancer. To date, he has authored 57 scientific papers and has been awarded 37 international and domestic patents.

Prior to joining 1ST Biotherapeutics, Jinhwa served as Director of the New Drug Research Center and acting Director of the Biotherapeutics Research Center at Handok. He was served as Director of the Late Discovery Program at Institut Pasteur Korea (IP-K) and prior to that, as Head of Medicinal Chemistry group at Green Cross Corporation (now, GC Pharma), leading many of drug discovery/development programs and their advancement into preclinical/clinicals stages in oncology, metabolic diseases, and infectious diseases. Jinhwa was Senior Investigator at GlaxoSmithKline in Collegeville, PA, where he also earned a five -year service appreciation award.

Jinhwa has a bachelor’s and master’s degree from Seoul National University. He achieved a Ph.D. in chemistry from the University of Alabama and completed his postdoctoral research at Harvard University.

Scientific Advisory Board

Scientific Advisory Board

Soon Myung Paik is a leading pathologist and Professor at Yonsei University College of Medicine, where he heads the Severance Biomedical Science Institute, the Yonsei Genome Center, and the Yonsei Institute for Personalized Cancer Therapy.

Prof. Paik has co-authored more than 120 peer-reviewed scientific articles, evaluating current protocol and therapies for breast and bowel cancers and the role of hormones and genes in driving tumor biology. In 2017, he was awarded the HOAM Prize in medicine and the Presidential Medal (South Korea).

Phil Hyu Lee is a practicing neurologist and Professor at Yonsei University’s Department of Neurology and Severance Biomedical Science Institute. He is an expert on Parkinson’s disease and has been recognized as a top Young Investigator by the Korean Neurological Association and the Korean Movement Disorders Society.

Prof. Lee is first or corresponding author on more than 100 peer-reviewed papers and serves on the editorial board of the Journal of Clinical Neurology.

Ae Nim Pae heads the Convergence Research Center for Diagnosis, Treatment and Care System of Dementia (DTC) at the Korea Institute of Science and Technology (KIST). She oversees both basic research and drug discovery for Alzheimer’s disease and dementia; conditions that are becoming and more and more prevalent with the aging of developed nations, but that still lack effective treatments.

Prior to joining the Convergence Research Center in 2012, Dr. Pae was the Head of the KIST Center for Neuro-Medicine. She is widely published in top journals and has received a Ministry of Science and ICT award, a Presidential Award (Korea), and a Prime Minister Award (Korea) for her scientific achievement.





주식회사 퍼스트바이오테라퓨틱스

경기도 성남시 분당구 판교역로 240 (삼환하이펙스 A동)

313호 (본사)

306호 (연구소)


1ST Biotherapeutics, Inc.

240 Pangyoyeok-ro, Sampyeong-dong, Bundang-gu, Seongnam-si, Gyeonggi-do, South Korea

Suite 313 (HQ)

Suite 306 (R&D)


031) 8023-5333 Fax
info@1stbio.com E-Mail